Skip to main content
Premium Trial:

Request an Annual Quote

Mesa Biotech Point-of-Care Testing Platform Garners CE Mark

NEW YORK (GenomeWeb) — Mesa Biotech said today that its PCR testing platform for point-of-care infectious disease testing has obtained CE marking in the EU.

The first available test in the EU market will be the company's Flu A/Flu B test.

The Accula System is a palm-sized device that accepts disposable test cassettes. The cassette contains all necessary reagents for lysis and nucleic acid amplification. The system does not require as much power as a standard thermal cycler, and can be run using a rechargeable battery pack. Readout is performed on a lateral flow strip, with results available in about 30 minutes.

"The introduction of the Accula System and its Flu A/Flu B test as our first PCR assay in the European market is an important validation of our platform and a critical strategic milestone for Mesa Biotech," Mesa CEO and Founder Hong Cai said in a statement. "Our proprietary assay design enables rapid development of a portfolio of cassettes to test for human, agricultural, food pathogens, or genetic disease targets."

In December, Mesa announced a distribution deal with Sekisui Diagnostics, which will exclusively distribute the Accula system and flu test in the US and Canada pending regulatory clearance in those countries.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.